Post job

Synergys Biotherapeutics CEO and executives

Executive Summary. Based on our data team's research, Dean M. Drako is the Synergys Biotherapeutics's CEO. Synergys Biotherapeutics has 200 employees, of which 12 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Synergys Biotherapeutics executive team is 25% female and 75% male.
  • 55% of the management team is White.
  • 17% of Synergys Biotherapeutics management is Hispanic or Latino.
  • 9% of the management team is Black or African American.
Work at Synergys Biotherapeutics?
Share your experience

Rate Synergys Biotherapeutics' leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
Dean M. Drako

CEO / President

Dean M. Drako's LinkedIn

Steve Roskowski

CTO

Steve Roskowski's LinkedIn

Tad Druart

Vice President Global Marketing

Tad Druart's LinkedIn

Hans Kahler

VP of Operations

Hans Kahler's LinkedIn

Ken Francis

President

Ken Francis's LinkedIn

Shaheen Kauser

Global Head of HR

Lynette Pon

Board Member

Rich Williams

Chief Financial Officer

Rich Williams's LinkedIn

Rishi Lodhia

Board Member

Rishi Lodhia's LinkedIn

Tijmen Vos

Vice President Product Management

Tijmen Vos's LinkedIn

Do you work at Synergys Biotherapeutics?

Does leadership effectively guide Synergys Biotherapeutics toward its goals?

Synergys Biotherapeutics jobs

Synergys Biotherapeutics founders

Name & TitleBio
Dean M. Drako

CEO / President

Dean M. Drako's LinkedIn

Synergys Biotherapeutics board members

Name & TitleBio
Dean M. Drako

CEO / President

Dean M. Drako's LinkedIn

Lynette Pon

Board Member

Rishi Lodhia

Board Member

Rishi Lodhia's LinkedIn

Ruben Castilla

Board Member

Ruben Castilla's LinkedIn

Synergys Biotherapeutics leadership demographics

Synergys Biotherapeutics gender distribution in management team

  • The Synergys Biotherapeutics executive team is 25% female and 75% male.
  • Synergys Biotherapeutics is 42% female and 58% male company-wide.
Male
Male
75%
Company-wide: 58%
Female
Female
25%
Company-wide: 42%

Synergys Biotherapeutics executives by race

Management Team:
  • The most common ethnicity among Synergys Biotherapeutics executive officers is White.
  • 55% of the management team is White.
  • 17% of Synergys Biotherapeutics's management is Hispanic or Latino.
  • 16% of the management team is Asian.
Company-wide:
  • White is the most common ethnicity company-wide.
  • 63% of employees are White.
  • 14% of employees are Hispanic or Latino.
  • 13% of employees are Black or African American.
  • Management team
  • General
100%
80%
60%
40%
20%
0%
Unknown
White
Black or African American
Asian
Hispanic or Latino

Synergys Biotherapeutics jobs nearby

Synergys Biotherapeutics executives FAQs

Zippia gives an in-depth look into the details of Synergys Biotherapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Synergys Biotherapeutics. The employee data is based on information from people who have self-reported their past or current employments at Synergys Biotherapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Synergys Biotherapeutics. The data presented on this page does not represent the view of Synergys Biotherapeutics and its employees or that of Zippia.

Synergys Biotherapeutics may also be known as or be related to Eagle Eye Networks, Eagle Eye Networks Inc, Eagle Eye Networks Inc., Eagle Eye Networks, Inc, Eagle Eye Networks, Inc. and Synergys Biotherapeutics.